RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stockwestcoast1000 - I think you summerized the past and now the present quite well. In the past 10 years ONCY has taken pelareorep through proof-of-concept, Phase 1 safety and efficacy trials, and now Phase 2 clinical trials in multiple cancers that are demonstrating efficacy and that pelareorep is a platform technology which can be used with various immunotherapies such as immune checkpoint inhibitors, CAR-T, bispecifics, and small molecule immuno-oncology agents.
As a result, Big Pharma has become most certainly aware of pelareorep's "bolt-on" acquisition potential since such a deal would help fend-off the looming patent-cliff challenge that Big Pharma is facing by 2025.
Bringing ONCY's pelareorep into Big Pharma's oncology franchise sooner than later would give the acquirer of ONCY a shortened timeframe to gain FDA/EMA marketing approval (i.e. accelerated approval) for pelareorep in combination with their IO agents and a shortened timeframe to run a post approval confirmatory trial (which ONCY is currently describing as a Phase 3 trial but can be better viewed as a post approval confirmatory trial). However the process, it would be ONCY's Big Pharma acquirer to decide on how they want to position pelareorep for both condicitonal and final regulatory approval, should they choose this pathway among several..